Cargando…

Efficacy of tolvaptan for fluid management after cardiovascular surgery: A systematic review and meta-analysis of randomized control trials

The purpose of this study was to systematically search the literature and analyze evidence from randomized controlled trials (RCTs) comparing tolvaptan with conventional diuretics for postoperative fluid management in cardiac surgery patients. An electronic search of PubMed, Scopus, BioMed Central,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Huiling, Jiang, Weihong, Li, Xiaogang, Meng, Zhaohui, Chen, Huamei, Li, Jiaying, Wang, Junwen, Zhao, Xiexiong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2020
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7401488/ https://www.ncbi.nlm.nih.gov/pubmed/32765752 http://dx.doi.org/10.3892/etm.2020.9007

Ejemplares similares

Predictive factors for responders to tolvaptan in fluid management after cardiovascular surgery
por: Kido, Takashi, et al.
Publicado: (2016)

Effects of Low-Dose Tolvaptan for Fluid Management After Cardiovascular Surgery
por: Matsuda, Yasuhiro, et al.
Publicado: (2022)

Relationship between vascular ageing and left ventricular geometry in patients with newly diagnosed primary aldosteronism
por: Huang, Miao, et al.
Publicado: (2022)

Butyric Acid Ameliorates Myocardial Fibrosis by Regulating M1/M2 Polarization of Macrophages and Promoting Recovery of Mitochondrial Function
por: Li, Xiaogang, et al.
Publicado: (2022)

Comparison of Efficacies of Commonly Used Hypertension Treatment Modalities: A Retrospective Study of 1900 Participants in a Hypertension Clinic
por: Zhao, Xiexiong, et al.
Publicado: (2020)

Efficacy and safety of tolvaptan for refractory fluid collection and edema in the terminal cancer patients
por: Tsuzuki, Norimasa, et al.
Publicado: (2023)

Optimal Patient Selection and Treatment Timing for Tolvaptan Therapy Following Cardiovascular Surgery
por: Horie, Kotaro, et al.
Publicado: (2023)

Tolvaptan
por: Rangarajan, Bharath, et al.
Publicado: (2014)

Tolvaptan Versus Fluid Restriction in the Treatment of Hyponatremia Resulting from SIADH Following Pituitary Surgery
por: Kleindienst, Andrea, et al.
Publicado: (2020)

Tolvaptan for Fluid Management in Living Donor Liver Transplant Recipients
por: Imai, Shunichi, et al.
Publicado: (2018)

Optimal Patient Selection and Treatment Timing for Tolvaptan Therapy Following Cardiovascular Surgery　― Reply ―
por: Matsuda, Yasuhiro, et al.
Publicado: (2023)

Efficacy of tolvaptan for the patients with advanced hepatocellular carcinoma
por: Miyazaki, Masayuki, et al.
Publicado: (2017)

Efficacy of tolvaptan for chronic heart failure: Study protocol for a systematic review of randomized controlled trial
por: Gao, Wei-qin, et al.
Publicado: (2019)

The efficacy of tolvaptan for heart failure in chronic kidney disease: A protocol for systematic review and meta-analysis
por: Zhu, Zhi-Yong, et al.
Publicado: (2022)

Evaluation of complications of administration for tolvaptan after fluid resuscitation in critical care
por: Arimoto, H, et al.
Publicado: (2015)

Total body fluid is the factor that affects the pharmacokinetics of tolvaptan, and its efficacy, in acute worsening heart failure patients
por: Kato, Takahiro, et al.
Publicado: (2023)

Hypertension doctors’ awareness and practice of medication adherence in hypertensive patients: a questionnaire-based survey
por: Liu, Tao, et al.
Publicado: (2023)

The NOCTURNE Randomized Trial Comparing 2 Tolvaptan Formulations
por: Perrone, Ronald D., et al.
Publicado: (2020)

Tolvaptan- and Tolvaptan-Metabolite-Responsive T Cells in Patients with Drug-Induced Liver Injury
por: Gibson, Andrew, et al.
Publicado: (2020)

Efficacy of tolvaptan on advanced chronic kidney disease with heart failure: a randomized controlled trial
por: Komiya, Shiro, et al.
Publicado: (2022)

Long-Term Outcomes of Longitudinal Efficacy Study With Tolvaptan in ADPKD
por: Higashihara, Eiji, et al.
Publicado: (2021)

Long-term low-dose tolvaptan efficacy and safety in SIADH
por: Bondanelli, Marta, et al.
Publicado: (2023)

Tolvaptan in reversing worsening acute heart failure: A systematic review and meta-analysis
por: Wang, Lili, et al.
Publicado: (2019)

The role of tolvaptan in pulmonary hypertension: A retrospective study
por: Chen, Qiaoli, et al.
Publicado: (2022)

The Efficacy and Renal Protective Effect of Tolvaptan in Chronic Kidney Disease Patients after Open-Heart Surgery
por: Futamura, Yasuhiro, et al.
Publicado: (2021)

Tolvaptan Reduces Extracellular Fluid per Amount of Body Fluid Reduction Less Markedly than Conventional Diuretics
por: Iwatani, Hirotsugu, et al.
Publicado: (2022)

Tolvaptan, hyponatremia, and heart failure
por: Zmily, Hammam D, et al.
Publicado: (2011)

Tolvaptan for the Treatment of Refractory Ascites
por: Kurosaki, Masayuki, et al.
Publicado: (2016)

Tolvaptan for water retention in heart failure: a systematic review
por: Pan, Yujing, et al.
Publicado: (2023)

Accuracy and stability evaluation of different blood sampling methods in blood gas analysis in emergency patients: A retrospective study
por: Zhao, Xiexiong, et al.
Publicado: (2022)

Dual Impact of Tolvaptan on Intracellular and Extracellular Water in Chronic Kidney Disease Patients with Fluid Retention
por: Masuda, Takahiro, et al.
Publicado: (2016)

Potential effect of tolvaptan on polycystic liver disease for patients with ADPKD meeting the Japanese criteria of tolvaptan use
por: Mizuno, Hiroki, et al.
Publicado: (2022)

A new method of intermittent lower dose of tolvaptan combined with fluid restriction to treat the syndrome of inappropriate antidiuresis: A case report
por: Yuan, Xianxian, et al.
Publicado: (2019)

Tolvaptan and its potential in the treatment of hyponatremia
por: Dixon, Megan B, et al.
Publicado: (2008)

V2 Receptor Antagonist; Tolvaptan
por: Yi, Joo-Hark, et al.
Publicado: (2011)

Predictors of the Effect of Tolvaptan on the Prognosis of Cirrhosis
por: Iwamoto, Takuya, et al.
Publicado: (2016)

The management of polycystic liver disease by tolvaptan
por: Takenaka, Tsuneo, et al.
Publicado: (2020)

Tolvaptan for the Treatment of Elephantiasis Nostras Verrucosa
por: Eda, Yuko, et al.
Publicado: (2019)

Efficacy and safety of tolvaptan versus placebo in the treatment of patients with autosomal dominant polycystic kidney disease: a meta-analysis
por: Lu, Jingkui, et al.
Publicado: (2022)

Tolvaptan Efficiently Reduces Intracellular Fluid: Working Toward a Potential Treatment Option for Cellular Edema
por: Kawabata, Hiroaki, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_19rknhqkd5206c4m6pdsj4a738